Background Oculo-auriculo-vertebral spectrum (OAVS) is a developmental disorder involving first and second branchial arches derivatives, mainly characterised by asymmetric ear anomalies, hemifacial microsomia, ocular defects and vertebral malformations. Although numerous chromosomal abnormalities have been associated with OAVS, no causative gene has been identified so far.
Objectives We aimed to identify the first causative gene for OAVS.
Methods As sporadic cases are mostly described in Goldenhar syndrome, we have performed whole exome sequencing (WES) on selected affected individuals and their unaffected parents, looking for de novo mutations. Candidate gene was tested through transient knockdown experiment in zebrafish using a morpholino-based approach. A functional test was developed in cell culture in order to assess deleterious consequences of mutations.
Results By WES, we identified a heterozygous nonsense mutation in one patient in the myelin transcription factor 1 (MYT1) gene. Further, we detected one heterozygous missense mutation in another patient among a cohort of 169 patients with OAVS. This gene encodes the MYT1. Functional studies by transient knockdown of myt1a, homologue of MYT1 in zebrafish, led to specific craniofacial cartilage alterations. Treatment with all-trans retinoic acid (RA), a known teratogenic agent causing OAVS, led to an upregulation of cellular endogenous MYT1 expression. Additionally, cellular wild-type MYT1 overexpression induced a downregulation of RA receptor β (RARB), whereas mutated MYT1 did not.
Conclusion We report MYT1 as the first gene implicated in OAVS, within the RA signalling pathway.
- Retinoic acid
- Goldenhar syndrome
Statistics from Altmetric.com
EL, MB and AT-S have equally contributed to this work. These first three authors should be considered as joint first authors.
Contributors EL, MB and AT-S planned, performed experiments, analysed data and co-wrote the manuscript; SM and AT clinically ascertained patients and provided samples; SC performed experiments and analysed data; FD and AP clinically ascertained patients; GM and HdB performed experiments; BA, PJB and DL planned experiments and CR supervised, planned experiments, analysed data, co-wrote and edited the manuscript.
Funding This work was supported by the ANR (Agence Nationale pour la Recherche, ANR-12-JVS1-0002), the University Hospital of Bordeaux (Appel Offre Interne GOLDGEN 2012), the Fondation Maladies Rares and the Ministry of Research and Higher Education (PhD fellowship for MB).
Competing interests None declared.
Patient consent Obtained.
Ethics approval CPP: DC 2012/76.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.